Trial NCT02054520

View at ClinicalTrials.gov 
Org. Study IDs: NLG0304
Secondary IDs: 1303-1217

Last trial update was posted on 2023-04-18

MeSH Interventions

Ipilimumab Nivolumab Pembrolizumab

MeSH Conditions

Melanoma

Other Conditions

Metastatic Melanoma Stage IV Melanoma

Stopping Reasons

Withdrawal of IND

Limitations And Caveats

Early termination leading to small numbers of subjects analyzed. The enrollment and treatment phase of this trial was terminated early and the IND has been closed.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID